Anti-CD19 x Anti-CD3 Bispecific Antibody (IgG-IgG) (BSIG-041)

Anti-CD19 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD19 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet

Specifications

Targets

CD19 & CD3

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD19

Host Animal 1

Mouse

Target 2

CD3

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

45-1 Ramsey Road, Shirley, NY 11967, USA
Email:
Fax: 1-631-207-8356
Or Call
Tel: 1-631-381-2994